The Fentanyl transdermal system utilizes a proprietary matrix design which incorporates the drug into the adhesive. It is indicated for the management of persistent moderate to severe chronic pain that requires continuous, around-the-clock opioid administration for an extended period of time and that cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids.
Teva’s Fentanyl transdermal system was developed and manufactured by Aveva Drug Delivery Systems, a Nitto Denko company, which is one of the manufacturers of ‘drug in adhesive’ transdermal patch technology.